 |
|
The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease
A Randomized Controlled Trial
Yoshihiro Sato, MD;
Tomohiro Kanoko, PhD;
Kei Satoh, MD;
Jun Iwamoto, MD
Arch Intern Med. 2005;165:1737-1742.
Background A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that deficiency of 25-hydroxyvitamin D and compensatory hyperparathyroidism cause reduced bone mineral density in female patients with AD. We address the possibility that treatment with risedronate sodium and ergocalciferol plus calcium supplementation may reduce the incidence of nonvertebral fractures in elderly women with AD.
Methods A total of 500 elderly women with AD were randomly assigned to daily treatment with 2.5 mg of risedronate sodium or a placebo, combined with 1000 IU of ergocalciferol and 1200 mg of elementary calcium, and followed up for 18 months.
Results At baseline, patients of both groups showed 25-hydroxyvitamin D deficiency with compensatory hyperparathyroidism. During the study period, bone mineral density in the risedronate group increased by 4.1% and decreased by 0.9% in the control group. Vertebral fractures occurred in 29 patients (24 hip fractures) in the control group and 8 patients (5 hip fractures) in the risedronate group. The relative risk in the risedronate group compared with the control group was 0.28 (95% confidence interval, 0.13-0.59).
Conclusions Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. Treatment with risedronate and ergocalciferol may be safe and effective in reducing the risk of a fracture in elderly patients with AD.
Author Affiliations: Department of Neurology (Dr Sato), Mitate Hospital, Tagawa; Departments of Rehabilitation Medicine (Dr Kanoko) and Vascular Biology (Dr Satoh), Hirosaki University School of Medicine, Hirosaki; and Department of Sports Medicine (Dr Iwamoto), Keio University School of Medicine, Tokyo; Japan.
RELATED LETTERS
Prevention of Hip Fracture in Elderly Women With Alzheimer Disease
Balavenkatesh Kanna and Estrella Roffe
Arch Intern Med. 2006;166(10):1144-1145.
EXTRACT
| FULL TEXT
Prevention of Hip Fracture in Elderly Women With Alzheimer Disease—Reply
Yoshihiro Sato, Tomohiro Kanoko, Kei Satoh, and Jun Iwamoto
Arch Intern Med. 2006;166(10):1145.
EXTRACT
| FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials
Jutta Martha Halbekath, Stefanie Schenk, Andreas von Maxen, Gabriele Meyer, and Ingrid Mühlhauser
Arch Intern Med. 2007;167(5):513-514.
EXTRACT
| FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials—Reply
Yoshihiro Sato
Arch Intern Med. 2007;167(5):514-515.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT
| FULL TEXT
Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials
Autier and Gandini
Arch Intern Med 2007;167:1730-1737.
ABSTRACT
| FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials--Reply
Sato
Arch Intern Med 2007;167:514-515.
FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials
Halbekath et al.
Arch Intern Med 2007;167:513-514.
FULL TEXT
Nutrition Support and the Chronic Critical Illness Syndrome
Hollander and Mechanick
Nutr Clin Pract 2006;21:587-604.
ABSTRACT
| FULL TEXT
Prevention of Hip Fracture in Elderly Women With Alzheimer Disease--Reply
Sato et al.
Arch Intern Med 2006;166:1145-1145.
FULL TEXT
Prevention of hip fracture in elderly women with Alzheimer disease.
Kanna and Roffe
Arch Intern Med 2006;166:1144-1145.
FULL TEXT
|
